Pfizer has slashed its full-year revenue forecast by around 13 per cent and launched a $US3.5 billion ($A5.6 billion) cost-cutting program due to lower-than-expected sales of its COVID-19 vaccine and treatment. The drugmaker said it now expected 2023 revenue of between $US58 billion and $US61 billion, down from it prior forecast of $US67 billion to […]

This post was originally published on Michael West.